Axsome Therapeutics Inc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All 19X.SG news ›Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its price target boosted by stock analysts at Morgan Stanley from $247.00 to $249.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an "equal…
Axsome Therapeutics: Sentiment Meets Reality After Q3 (Rating Upgrade)
Axsome Therapeutics is upgraded to Hold as valuation resets after ADA approval. Read the latest analysis on AXSM stock here. - Axsome Therapeutics is upgraded to 'Hold' as its valuation now better reflects commercial realities post-ADA…
Axsome Therapeutics (NASDAQ:AXSM) Stock Gets Price Target Reduction from Robert W. Baird
Posted by Tristan Rich on Nov 3rd, 2026 Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target decreased by stock analysts at Robert W. Baird from $246.00 to $220.00 in a research note issued to investors on Tuesday,…
What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call
Posted by Sarita Garza on Nov 3rd, 2026 Axsome Therapeutics (NASDAQ:AXSM) reported third-quarter revenue growth of 52% year over year, driven primarily by continued expansion of AUVELITY sales in major depressive disorder and Alzheimer’s…
More from 1 other outlet
Axsome Therapeutics 3Q 2026: Revenue $259.7M, Net loss $12.9M, EPS $(0.25) — 10-Q Summary
TradingView - Revenue was $259.7M, compared with $171.0M in the prior-year quarter; YoY change 51.9%. - Net loss was $12.9M, compared with $47.2M in the prior-year quarter. - Nine-month revenue increased 51% ye
Axsome Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-02. The following slide deck was published by Axsome Therapeutics, Inc. The following slide deck was published by Axsome Therapeutics, Inc. in conjunction with their 2026 Q3 earnings call.
More from 1 other outlet
Ensysce Biosciences (NASDAQ:ENSC) & Axsome Therapeutics (NASDAQ:AXSM) Financial Review
Posted by Mitch Edgeman on Oct 31st, 2026 Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) and Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?
Axsome Therapeutics (AXSM -1.99%) has recorded a compound annual growth rate of 29.06% over the past five years. If the company can maintain that pace over the next nine years, it could turn $5,000 into $49,670. But can the biotech pull…
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility
It formally initiated an extensive late-stage clinical trial evaluating solriamfetol as a targeted treatment for pediatric attention deficit hyperactivity disorder, and the U.S. Food and Drug Administration officially accepted its newly…
Axsome Therapeutics (AXSM) Projected to Post Quarterly Earnings on Monday
Read Our Latest Analysis on Axsome Therapeutics Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com6
- themarketsdaily.com6
- marketscreener.com5
- seekingalpha.com5
- fool.com4
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 36 articles, not a forecast.